Amyloid deposition, hypometabolism, and longitudinal cognitive decline.
Amyloid deposition, hypometabolism, and longitudinal cognitive decline.
复制标题
DOI：
10.1002/ana.23650
复制
发表时间：
2012-10
影响因子：
11.2
通讯作者：
Jagust, William J.
中科院分区：
文献类型：
--
作者：
Landau, Susan M.;Mintun, Mark A.;Joshi, Abhinay D.;Koeppe, Robert A.;Petersen, Ronald C.;Aisen, Paul S.;Weiner, Michael W.;Jagust, William J.
利用阿尔茨海默病神经影像学倡议（ADNI）人群的数据，我们研究了（1）淀粉样蛋白沉积、代谢低下和认知之间的横截面关系，以及（2）淀粉样蛋白和代谢低下测量与纵向认知测量之间的关联。我们检查了426名ADNI参与者（126名正常，162名早期轻度认知障碍[EMCI]，85名晚期MCI [LMCI]，53名阿尔茨海默病[AD]患者）的平均皮质氟倍他平摄取，一组预定义区域内的平均18 F-氟脱氧葡萄糖-正电子发射断层扫描（FDG-PET）和阿尔茨海默病评估量表（ADAS-cog）性能之间的相关性。对于其中的一个子集（76例正常，81例LMCI），我们确定了氟倍他平和FDG-PET是否与纵向ADAS-cog测量的回顾性下降相关。29%的正常受试者、43%的EMCI患者、62%的LMCI患者和77%的AD患者被归类为florbetapir阳性。在两个MCI组中，Florbetapir与同期FDG和ADAS-cog呈负相关。在纵向分析中，正常组和LMCI组中的florbetapir阳性受试者的ADAS-cog持续下降幅度大于florbetapir阴性受试者。然而，在正常受试者中，florbetapir阳性与ADAS-cog下降的相关性大于FDG，而在LMCI中，FDG阳性与ADAS-cog下降的相关性大于florbetapir。尽管在正常受试者和所有诊断组中均可检测到代谢低下和β-淀粉样蛋白（Aβ）沉积，但Aβ与正常参与者的认知能力下降有更大的相关性。鉴于该组总体上认知恶化最小，这表明淀粉样蛋白沉积对代谢变化之前的认知具有早期和亚临床影响。在疾病的中度和晚期（LMCI/AD），代谢低下变得更加明显，与持续的认知能力下降更密切相关。
Using data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) population, we examined (1) cross-sectional relationships between amyloid deposition, hypometabolism, and cognition, and (2) associations between amyloid and hypometabolism measurements and longitudinal cognitive measurements. We examined associations between mean cortical florbetapir uptake, mean 18F-fluorodeoxyglucose–positron emission tomography (FDG-PET) within a set of predefined regions, and Alzhiemer’s Disease Assessment Scale (ADAS-cog) performance in 426 ADNI participants (126 normal, 162 early mild cognitive impairment [EMCI], 85 late MCI [LMCI], 53 Alzheimer disease [AD] patients). For a subset of these (76 normal, 81 LMCI) we determined whether florbetapir and FDG-PET were associated with retrospective decline in longitudinal ADAS-cog measurements. Twenty-nine percent of normal subjects, 43% of EMCI patients, 62% of LMCI patients, and 77% of AD patients were categorized as florbetapir positive. Florbetapir was negatively associated with concurrent FDG and ADAS-cog in both MCI groups. In longitudinal analyses, florbetapir-positive subjects in both normal and LMCI groups had greater ongoing ADAS-cog decline than those who were florbetapir negative. However, in normal subjects, florbetapir positivity was associated with greater ADAS-cog decline than FDG, whereas in LMCI, FDG positivity was associated with greater decline than florbetapir. Although both hypometabolism and β-amyloid (Aβ) deposition are detectable in normal subjects and all diagnostic groups, Aβ showed greater associations with cognitive decline in normal participants. In view of the minimal cognitive deterioration overall in this group, this suggests that amyloid deposition has an early and subclinical impact on cognition that precedes metabolic changes. At moderate and later stages of disease (LMCI/AD), hypometabolism becomes more pronounced and more closely linked to ongoing cognitive decline.
登录
查看更多内容
影响因子：
--
作者：
Massoud, F;Devi, G;Mayeux, R
通讯作者：
Mayeux, R
影响因子：
3.7
作者：
Ewers, Michael;Insel, Philip;Weiner, Michael W.
通讯作者：
Weiner, Michael W.
影响因子：
9.9
作者：
Jagust, W. J.;Landau, S. M.;Mathis, C. A.
通讯作者：
Mathis, C. A.
影响因子：
3
作者：
Chetelat, Gael;Villemagne, Victor L.;Rowe, Christopher C.
通讯作者：
Rowe, Christopher C.
DOI：
10.1001/jama.2010.2008
发表时间：
2011-01-19
期刊：
JAMA
影响因子：
--
作者：
Clark CM;Schneider JA;Bedell BJ;Beach TG;Bilker WB;Mintun MA;Pontecorvo MJ;Hefti F;Carpenter AP;Flitter ML;Krautkramer MJ;Kung HF;Coleman RE;Doraiswamy PM;Fleisher AS;Sabbagh MN;Sadowsky CH;Reiman EP;Zehntner SP;Skovronsky DM;AV45-A07 Study Group
通讯作者：
AV45-A07 Study Group